iPSC-Derived T and CAR-T Cells of Distinct Phenotypes: Current Protocols, Challenges and Potential for Cancer Treatment
Cells · 2026
DOI: 10.3390/cells15211938 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Margarita Maiak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Centre for Medical Genetics, 1 Moskvorechye St., Moscow 115522, Russia. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: state assignment of the Federal State Budgetary Scientific Institution “Research Centre for Medical Genetics” of the Ministry of Science and Higher Education o….
Abstract (Originalsprache)
Adoptive T-cell therapy has demonstrated substantial clinical efficacy in several hematological malignancies, but autologous manufacturing remains limited by variability in starting cell material, manufacturing time, product heterogeneity, and T-cell dysfunction. Induced pluripotent stem cells (iPSCs) provide a potentially scalable and genetically engineerable source for the generation of standardized allogeneic T-cell products. This review summarizes current approaches to the differentiation of iPSCs into distinct T-cell phenotypes and evaluates their potential for cancer immunotherapy. We first discuss iPSC-derived conventional αβ T cells, including recent advances in feeder-free and scalable differentiation, maturation, and genetic engineering, as well as preclinical and early clinical evidence. We then examine γδ T cells, invariant natural killer T cells, and mucosal-associated invariant T cells, focusing on their distinctive antigen-recognition mechanisms, effector functions, tissue tropism, differentiation strategies, and therapeutic applications. Across these populations, iPSC technology may facilitate standardized and scalable production while enabling targeted engineering of T-cell specificity and functional properties. However, important challenges remain, including efficient lineage-specific differentiation, maturation, phenotypic consistency, long-term persistence, tumor infiltration, and control of alloreactivity and immunogenicity. Overall, iPSC-derived T cells represent a versatile platform for developing diverse cellular immunotherapies, although their clinical potential remains dependent on further technological and translational advances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Centre for Medical Genetics, 1 Moskvorechye St., Moscow 115522, Russia.
ORCID-Profile: Margarita Maiak, Tatiana Budagova, Diana Mokrousova
Förderung
- state assignment of the Federal State Budgetary Scientific Institution “Research Centre for Medical Genetics” of the Ministry of Science and Higher Education o…
Zitieren
APA
Maiak, M., Efremova, A., Budagova, T., Mokrousova, D., & Goldshtein, D. (2026). iPSC-Derived T and CAR-T Cells of Distinct Phenotypes: Current Protocols, Challenges and Potential for Cancer Treatment. Cells. https://doi.org/10.3390/cells15211938
Vancouver
Maiak M, Efremova A, Budagova T, Mokrousova D, Goldshtein D. iPSC-Derived T and CAR-T Cells of Distinct Phenotypes: Current Protocols, Challenges and Potential for Cancer Treatment. Cells. 2026. doi:10.3390/cells15211938
BibTeX
@article{Maiak2026,
author = {Maiak, Margarita and Efremova, Anna and Budagova, Tatiana and Mokrousova, Diana and Goldshtein, Dmitry},
title = {iPSC-Derived T and CAR-T Cells of Distinct Phenotypes: Current Protocols, Challenges and Potential for Cancer Treatment},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15211938}
}
EUVIMED